Topiramate's Effects on Heavy Drinking



Status:Terminated
Conditions:Psychiatric
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:18 - 60
Updated:9/23/2018
Start Date:May 2015
End Date:March 2017

Use our guide to learn which trials are right for you!

Brain Mechanisms of Topiramate's Effects on Heavy Drinking

The proposed project will utilize perfusion functional magnetic resonance imaging (fMRI) to
examine the effects of topiramate on brain and behavioral responses in heavy drinkers to
appetitive alcohol reminders (cues that motivate continued alcohol use and relapse). This
project will yield novel findings on brain and behavioral responses to alcohol cues, the
effects of topiramate on alcohol cue reactivity, and the mechanisms underlying topiramate's
ability to blunt alcohol cue reactivity and heavy drinking.

This project is a double-blind, randomized, placebo-controlled study of topiramate's effects
on brain and behavior responses in heavy drinkers. Eligible volunteers who meet study
criteria will be randomized to receive either topiramate or placebo with weekly visits and
medication management sessions. Participants will complete two magnetic resonance imaging
sessions. The first scan session will occur prior to starting study drug, and the second scan
will occur following six weeks of study drug. This project will yield novel findings on brain
and behavioral responses to alcohol cues, the effects of topiramate on alcohol cue
reactivity, and the mechanisms underlying topiramate's ability to blunt alcohol cue
reactivity and heavy drinking.

Inclusion Criteria:

- Physically healthy, as determined by a comprehensive physical examination and approval
of the study physician, males or females who drink alcohol, ages 18-60.

- Average weekly ethanol consumption of >24 standard drinks for men, or >18 standard
drinks for women.

- Females must be non-pregnant, non-lactating and either be of non-childbearing
potential (i.e. sterilized via hysterectomy or bilateral tubal ligation or at least 2
years postmenopausal) or of child bearing potential but practicing a medically
acceptable method of birth control. Examples of medically acceptable methods for this
protocol include: the birth control pill, intrauterine device, injection of
Depo-Provera, Norplant, contraceptive patch, contraceptive ring, double-barrier
methods (such as condoms and diaphragm/spermicide), male partner sterilization,
abstinence (and agreement to continue abstinence or to use an acceptable method of
contraception, as listed above, should sexual activity commence), and tubal ligation.

- Provide voluntary informed consent.

- Must be able to read. [Subjects are required to be able to read because there are
several self-administered measures that they must read, understand and provide written
answers.]

- Intelligence quotient of ≥ 80.

Exclusion Criteria:

- Current, clinically significant physical disease or abnormality on the basis of
medical history, physical examination, or routine laboratory evaluation.

- History of head trauma or injury causing loss of consciousness, lasting more than five
(5) minutes or associated with skull fracture or inter-cranial bleeding or abnormal
MRI.

- Current major DSM-IV Axis I diagnoses other than alcohol use disorder (except nicotine
use disorder).

- Presence of magnetically active irremovable prosthetics, plates, pins, permanent
retainer, bullets, etc. (unless a radiologist confirms that it's presence is
unproblematic). An x-ray may be obtained to determine eligibility given the
possibility of a foreign body.

- History of a serious psychiatric illness including psychosis, bipolar disorder, or
suicidal or homicidal intent.

- Current treatment with carbonic anhydrase inhibitors.

- Claustrophobia or other medical condition preventing subject from lying in the MRI for
approximately one (1) hour.

- Current regular treatment with psychotropic medications (e.g., benzodiazepines,
antidepressants), which affect neurotransmitter systems or a medication being used to
treat alcohol use disorders (e.g., naltrexone, acamprosate).

- Vision problems that cannot be corrected with glasses.

- Body Mass Index (BMI) greater than or equal to 34, body girth greater than 52 inches
and a head girth greater than 25 inches.

- History of stroke and/or stroke related spasticity.

- History of glaucoma or kidney stones.

- HIV positive.

- History of seizures.

- History of topiramate treatment for alcohol use disorder and report no treatment
response.

- Current DSM-5 diagnosis of alcohol use disorder that is clinically too severe to
permit them to participate in a research trial in which the goal is to stop or reduce
drinking.
We found this trial at
1
site
Philadelphia, Pennsylvania 19104
Principal Investigator: Reagan R Wetherill, PhD
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials